Search This Blog

Wednesday, March 31, 2021

FDA OKs Sanofi Sarclisa combo for relapsed or refractory multiple myeloma

 

  • Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies

  • While the median progression free survival (PFS) for Sarclisa combination therapy is not yet reached, consistent improvement in PFS is seen across patient subgroups

  • This is the second FDA approval for Sarclisa in combination with standard of care backbone therapies

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.